Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression

Leuk Res. 2010 Sep;34(9):e254-6. doi: 10.1016/j.leukres.2010.03.032. Epub 2010 Apr 14.

Authors

Sotirios G Papageorgiou, Vasiliki Pappa, Christina Economopoulou, Panagiotis Tsirigotis, Frida Konsioti, Eleni-Dikaia Ionnidou, Spyros Chondropoulos, Diamantina Vasilatou, Efstathios Papageorgiou, Theofanis Economopoulos, John Dervenoulas

PMID: 20392492
DOI: 10.1016/j.leukres.2010.03.032

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Central Nervous System Neoplasms / secondary*
Dasatinib
Drug Resistance, Neoplasm
Humans
Imatinib Mesylate
Karyotyping
Leukemia, Megakaryoblastic, Acute / drug therapy*
Leukemia, Megakaryoblastic, Acute / genetics
Leukemia, Megakaryoblastic, Acute / pathology
Male
Middle Aged
Philadelphia Chromosome*
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Remission Induction
Thiazoles / therapeutic use*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Thiazoles
Imatinib Mesylate
Dasatinib